Emplicure Interim Report Q1 2022

First quarter, 1 January - 31 March 2022

• Net revenue totalled 0.0 (0.0) MSEK
• EBIT totalled -7.3 (-0.9) MSEK
• EBITDA totalled -7.3 (-1.3) MSEK
• Cash flow totalled -5.6 (+9.5) MSEK
• Earnings per share -0.36 (-0.12) SEK

Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: [email protected]

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: [email protected]

Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on April 26, 2022 at 08:30 CET.

The following documents can be retrieved from beQuoted
PM-Emplicure-AB-Q1-Report-2022-Significantly-longer-release.pdf
Emplicure-Interim-Report-Q1-2022-ENG.pdf

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white oral nicotine pouches as the first product. Read more at www.emplicure.com

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.